MEIP News and Press, MEI Pharma Inc. From 02/20/24

2024-02-20 17:42:00 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Read the full article on Seeking Alpha For further details see: MEI Pharma files for $100M mixed shelf

2024-02-13 17:19:53 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Financial information for MEI Pharma Read the full article on Seeking Alpha For further details see: MEI Pharma GAA...

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate even...

2024-02-11 09:35:00 ET Summary GreenWood Investors is a bottom-up, mostly long, concentrated and constructivist global investment firm focused on areas of pessimism, structural inefficiencies and low competition. In terms of 2023 returns, our separate accounts, which remain open t...

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

– Ongoing Phase 1b Study Evaluating ME-344 Plus Avastin® in Patients with Metastatic Colorectal Cancer: Combination Intended to Create Metabolic Synthetic Lethality – MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candid...

2023-12-18 03:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own MEI Pharma stock, would like to learn more about these claim...

– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity – – Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol II p-S2 – MEI Pharma, Inc. (Nasdaq:...

2023-11-09 17:42:54 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma For further details see: MEI Pharma GAAP EPS of $8.46, revenue of $65.3M